RecruitingNCT05025605
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolarity
Medication studyAges 10–17United States
Understand this study
Who could participate?
Listed age limits: 10 years to 17 years.
- Listed locations
- Anaheim and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: August 27, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 140
- Sponsor
- BioXcel Therapeutics Inc
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT05025605
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Anaheim · Hialeah · Atlanta
2 more locations
- Decatur
- DeSoto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BioXcel Therapeutics Inc.
Does this study involve medication?
Yes. The study involves medication, including BXCL501 80 Micrograms, Placebo Film, BXCL501 120 Micrograms and BXCL501 60 Micrograms.
Who can participate?
Listed age limits: 10 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
